Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Andrew A. Lane, MD, PhD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Center
  • Associate Professor of Medicine, Harvard Medical School
  • Physician

Centers/Programs

Clinical Interests

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  • Leukemias
  • Stem cell transplantation

Diseases Treated

Contact Information

  • Appointments617-632-6140
  • Office Phone Number617-582-7386
  • Fax617-632-2933

Bio

Dr. Lane received his MD and PhD degrees from Washington University. He completed his residency in internal medicine at Brigham and Women's Hospital, and his fellowships in hematology and medical oncology at DFCI. His research focuses on developing new treatments for leukemia by studying the genetic changes that occur in cancer and how they alter the normal development of blood cells.

VIDEO:

Andrew Lane, MD, PhD, is a physician in Dana-Farber’s Adult Leukemia program. He treats patients with acute leukemias and blastic plasmacytoid dendritic cell neoplasm (BPDCN). In this video, Dr. Lane shares that working in oncology is very fulfilling for the combination of patient care and cutting-edge research and medicine. Learn more about the Adult Leukemia Program: http://www.dana-farber.org/adult-leukemia-program/

Board Certification:

  • Hematology, 2012
  • Internal Medicine, 2009
  • Medical Oncology, 2012

Fellowship:

  • Dana-Farber/Partners CancerCare, Hematology/Oncology

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Washington University

Recent Awards:

  • Seldin-Smith Award for Pioneering Research, American Society for Clinical Investigation (ASCI), 2020

Research

Developing new treatments for leukemia

The Lane lab strives to expose and target the abnormal biology that drives blood cancers, particularly those with poor prognoses or without specific treatments.  We focus predominantly on acute leukemia and the disruption of normal stem cell development in hematologic malignancies.

Our goal is to understand the genetic and epigenetic changes that alter gene regulation in malignant hematopoietic cells, develop innovative model systems to study those abnormalities, and ultimately discover novel therapeutic strategies.  We hope that our research leads to better tolerated therapies and more cures for patients with leukemia and other blood disorders.

We are also committed to training the next generation of physicians and scientists who will be future leaders in cancer research and clinical-translational innovation.

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 May 06; 137(18):2463-2480.
View in: PubMed

Targeting CD123 in AML. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S67-S68.
View in: PubMed

Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. Leuk Lymphoma. 2020 09; 61(9):2258-2261.
View in: PubMed

Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020 03 24; 4(6):1006-1011.
View in: PubMed

Blastic Plasmacytoid Dendritic Cell Neoplasm in 2020 and Beyond. Hematol Oncol Clin North Am. 2020 06; 34(3):xiii-xiv.
View in: PubMed

Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 06; 34(3):589-600.
View in: PubMed

Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat Commun. 2020 03 16; 11(1):1406.
View in: PubMed

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019 11 01; 129(11):5005-5019.
View in: PubMed

Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):941-946.
View in: PubMed

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687.
View in: PubMed

Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):545-554.
View in: PubMed

Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature. J Glob Oncol. 2019 06; 5:1-6.
View in: PubMed

Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508.
View in: PubMed

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 04 25; 380(17):1628-1637.
View in: PubMed

Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Res. 2019 06; 29(6):446-459.
View in: PubMed

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019 03 07; 176(6):1265-1281.e24.
View in: PubMed

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. N Engl J Med. 2019 02 14; 380(7):695-6.
View in: PubMed

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. Curr Hematol Malig Rep. 2018 12; 13(6):581-587.
View in: PubMed

Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. Cell Rep. 2018 11 13; 25(7):1898-1911.e5.
View in: PubMed

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. Curr Hematol Malig Rep. 2017 12; 12(6):592-597.
View in: PubMed

Monogenic Hashimoto thyroiditis associated with a variant in the thyroglobulin (TG) gene. J Autoimmun. 2018 01; 86:116-119.
View in: PubMed

Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening. Blood Adv. 2017 Aug 22; 1(19):1491-1494.
View in: PubMed

Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017 04 21; 356(6335).
View in: PubMed

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164.
View in: PubMed

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Curr Hematol Malig Rep. 2016 12; 11(6):462-467.
View in: PubMed

Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017 01; 49(1):10-16.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
View in: PubMed

Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1046-1053.
View in: PubMed

Mutations in G protein ß subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015 Jan; 21(1):71-5.
View in: PubMed

Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 2014 Nov 11; 3(5):832-40.
View in: PubMed

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8.
View in: PubMed

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23.
View in: PubMed

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014 Feb 27; 123(9):1293-6.
View in: PubMed

Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013 May 24; 3:e117.
View in: PubMed

Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013 Apr; 27(4):968-71.
View in: PubMed

Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One. 2012; 7(11):e49201.
View in: PubMed

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012 Feb 13; 209(2):259-73.
View in: PubMed

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6.
View in: PubMed

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55.
View in: PubMed

High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma. 2011 Jul; 52(7):1363-6.
View in: PubMed

Stem cells and DNA damage: persist or perish? Cell. 2010 Aug 06; 142(3):360-2.
View in: PubMed

A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood. 2010 Nov 04; 116(18):3604-10.
View in: PubMed

von Willebrand disease type 2N: uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy. Am J Hematol. 2010 Feb; 85(2):134-5.
View in: PubMed

Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009 Nov 10; 27(32):5459-68.
View in: PubMed

Acute myeloid leukemia in first complete remission: How do we select patients for allogeneic stem cell transplantation?. American Journal of Hematology/Oncology. 2009; 8(10):508-511.

Pathogenesis of acute promyelocytic leukemia [dissertation]. 2006.

Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica. 2005 Aug; 90(8):1042-9.
View in: PubMed

Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells. Mol Cell Biol. 2005 Jan; 25(1):23-33.
View in: PubMed

Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol. 2004 Dec; 24(24):10882-93.
View in: PubMed

Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell. 2003 Oct 31; 115(3):305-18.
View in: PubMed

High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood. 2003 Sep 01; 102(5):1857-65.
View in: PubMed

Mouse models of acute promyelocytic leukemia. Curr Opin Hematol. 2001 Jul; 8(4):206-11.
View in: PubMed

Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J. 1999 Apr 15; 18(8):2165-73.
View in: PubMed

Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 1998 Mar 01; 12(5):667-78.
View in: PubMed

Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem. 1998 Jan 16; 273(3):1303-8.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Mayer 413
Boston, MA 02215
Get Directions

Ratings

Top